Syncromune is advancing SYNC-T Therapy SV-102 in the ongoing Phase 2 LEGION-100 study (NCT06533644), which is actively enrolling across multiple sites in the U.S. Please visit www.legion100trial.com ...
From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...
Immunotherapy is a cancer treatment that harnesses the body’s immune system to fight cancer. It helps the immune system recognize and attack cancer cells, which can sometimes be hidden from the body’s ...
Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...
SurvivorNet on MSN
Inlexzo: A new option for bladder cancer patients when BCG immunotherapy stops working
If you or a loved one has been diagnosed with BCG-unresponsive non-muscle invasive bladder cancer and are exploring your ...
Neoadjuvant immunotherapy is expanding treatment options in CSCC by shrinking complex tumors, improving surgical outcomes, ...
Dr. David Greenberg outlines bladder cancer staging, BCG, immunotherapy, surgery, quality of life impacts and long-term ...
A comprehensive new review led by Mayo Clinic is helping shape how clinicians diagnose and treat meningioma, the most common primary brain tumor, with a focus on personalized, patient-centered care ...
St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the rest of the immune system to the presence of cancer—and how restoring their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results